Valneva SE: Chikungunya Outbreak on a French Island - Valneva is to Deliver at Least 40,000 Vaccine Doses

Valneva SE (i.) specializes in vaccines for infectious diseases with high unmet needs. The current portfolio includes three travel vaccines: IXIARO, a vaccine against Japanese encephalitis, DUKORAL, an orally administered vaccine against cholera, and IXCHIQ, the world's first approved vaccine against the Chikungunya virus, which was approved in 2023 by the FDA, Health Canada, and the EMA. The approval of the Chikungunya vaccine represented a significant milestone, as the virus is on the rise globally and no specific treatment exists. With a...